These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37543490)

  • 1. Early prediction of pathologic complete response of breast cancer after neoadjuvant chemotherapy using longitudinal ultrafast dynamic contrast-enhanced MRI.
    Cao Y; Wang X; Li L; Shi J; Zeng X; Huang Y; Chen H; Jiang F; Yin T; Nickel D; Zhang J
    Diagn Interv Imaging; 2023 Dec; 104(12):605-614. PubMed ID: 37543490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies.
    Ramtohul T; Tescher C; Vaflard P; Cyrta J; Girard N; Malhaire C; Tardivon A
    Radiology; 2022 Dec; 305(3):565-574. PubMed ID: 35880977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple parameters from ultrafast dynamic contrast-enhanced magnetic resonance imaging to discriminate between benign and malignant breast lesions: Comparison with apparent diffusion coefficient.
    Cao Y; Wang X; Shi J; Zeng X; Du L; Li Q; Nickel D; Zhou X; Zhang J
    Diagn Interv Imaging; 2023 Jun; 104(6):275-283. PubMed ID: 36739225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer using a combination of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging.
    Han X; Yang H; Jin S; Sun Y; Zhang H; Shan M; Cheng W
    Cancer Med; 2023 Jan; 12(2):1389-1398. PubMed ID: 35822639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer.
    Liang X; Chen X; Yang Z; Liao Y; Wang M; Li Y; Fan W; Dai Z; Zhang Y
    BMC Cancer; 2022 Dec; 22(1):1250. PubMed ID: 36460972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer.
    Ren Z; Pineda FD; Howard FM; Fan X; Nanda R; Abe H; Kulkarni K; Karczmar GS
    Magn Reson Imaging; 2023 Dec; 104():9-15. PubMed ID: 37611646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
    Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results.
    Abramson RG; Li X; Hoyt TL; Su PF; Arlinghaus LR; Wilson KJ; Abramson VG; Chakravarthy AB; Yankeelov TE
    Magn Reson Imaging; 2013 Nov; 31(9):1457-64. PubMed ID: 23954320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrafast dynamic contrast-enhanced breast MRI: association with pathologic complete response in neoadjuvant treatment of breast cancer.
    Kim JH; Park VY; Shin HJ; Kim MJ; Yoon JH
    Eur Radiol; 2022 Jul; 32(7):4823-4833. PubMed ID: 35064805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Prediction of Response to Neoadjuvant Chemotherapy Using Dynamic Contrast-Enhanced MRI and Ultrasound in Breast Cancer.
    Kim Y; Kim SH; Song BJ; Kang BJ; Yim KI; Lee A; Nam Y
    Korean J Radiol; 2018; 19(4):682-691. PubMed ID: 29962874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
    Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
    Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing pathological complete response prediction in breast cancer: the role of dynamic characterization of DCE-MRI and its association with tumor heterogeneity.
    Zhang X; Teng X; Zhang J; Lai Q; Cai J
    Breast Cancer Res; 2024 May; 26(1):77. PubMed ID: 38745321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.
    Li Y; Chen Y; Zhao R; Ji Y; Li J; Zhang Y; Lu H
    Eur Radiol; 2022 Mar; 32(3):1676-1687. PubMed ID: 34767068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of ultrafast and standard dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the presence and extension of residual disease after neoadjuvant chemotherapy in breast cancer.
    Kato E; Mori N; Mugikura S; Sato S; Ishida T; Takase K
    Jpn J Radiol; 2021 Aug; 39(8):791-801. PubMed ID: 33743147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer.
    Onishi N; Sadinski M; Hughes MC; Ko ES; Gibbs P; Gallagher KM; Fung MM; Hunt TJ; Martinez DF; Shukla-Dave A; Morris EA; Sutton EJ
    Breast Cancer Res; 2020 May; 22(1):58. PubMed ID: 32466799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
    Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
    Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.
    Li X; Abramson RG; Arlinghaus LR; Kang H; Chakravarthy AB; Abramson VG; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Grau AM; Sanders M; Yankeelov TE
    Invest Radiol; 2015 Apr; 50(4):195-204. PubMed ID: 25360603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer.
    Musall BC; Abdelhafez AH; Adrada BE; Candelaria RP; Mohamed RMM; Boge M; Le-Petross H; Arribas E; Lane DL; Spak DA; Leung JWT; Hwang KP; Son JB; Elshafeey NA; Mahmoud HS; Wei P; Sun J; Zhang S; White JB; Ravenberg EE; Litton JK; Damodaran S; Thompson AM; Moulder SL; Yang WT; Pagel MD; Rauch GM; Ma J
    J Magn Reson Imaging; 2021 Jul; 54(1):251-260. PubMed ID: 33586845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Multiparametric MRI Radiomics-Based Nomogram in Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Two-Center study.
    Wang X; Hua H; Han J; Zhong X; Liu J; Chen J
    Clin Breast Cancer; 2023 Aug; 23(6):e331-e344. PubMed ID: 37321954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy.
    Wu J; Gong G; Cui Y; Li R
    J Magn Reson Imaging; 2016 Nov; 44(5):1107-1115. PubMed ID: 27080586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.